<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00104598</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-13334-6</org_study_id>
    <secondary_id>P50DA013334</secondary_id>
    <secondary_id>P50-13334-6</secondary_id>
    <nct_id>NCT00104598</nct_id>
  </id_info>
  <brief_title>Framing Messages for Smoking Cessation With Bupropion - 6</brief_title>
  <official_title>Framing Messages for Smoking Cessation With Buproprion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized study of message framing in individuals beginning a smoking cessation
      program utilizing bupropion SR and brief counseling, videos, and pamphlets.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Smoking Cessation at 7 days</measure>
    <time_frame>7-day point prevalence abstinence</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Continuous Smoking Abstinence at 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>6-week continuous abstinence.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">252</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Gain Framed Absitnence Program</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gain framed video and printed messages encouraging smoking abstinence with Bupropion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Loss Framed Abstinence Program</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loss framed video and printed messages encouraging smoking abstinence with Bupropion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <arm_group_label>Gain Framed Absitnence Program</arm_group_label>
    <arm_group_label>Loss Framed Abstinence Program</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Smoking Abstinence Program</intervention_name>
    <description>This investigation was a randomized controlled study of two framed message conditions for smoking cessation in combination with open label bupropion SR (300 mg/day). Two hundred fifty-eight cigarette smokers were randomly assigned to receive either gain- or loss-framed video and printed messages encouraging smoking abstinence. Preproduced video and printed information were chosen as the intervention media because of their reliability in delivering specific framed messages. All participants were seen at a community mental health center for 6 months and received a 7-week supply of bupropion SR.</description>
    <arm_group_label>Gain Framed Absitnence Program</arm_group_label>
    <arm_group_label>Loss Framed Abstinence Program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Exclusion Criteria:

          -  Pregnant or nursing women, or women of child-bearing potential who are not using an
             adequate method of contraception

          -  Psychiatric illnesses requiring psychotropic medications (i.e., psychosis, major
             depression, mania), or the presence of suicidality or homocidality

          -  Current use of nicotine replacement therapies (i.e., nicotine patch, gum, or lozenges,
             nasal spray, or inhaler), bupropion (Zyban, Wellbutrin), or marijuana or current
             participation in another smoking cessation treatment

          -  Presence of unstable medical conditions (i.e., cardiac, hepatic, renal disease,
             diabetes mellitus) that would make a trial of bupropion SR hazardous

          -  Have taken monoamine oxidase inhibitors or metoprolol succinate within the past six
             weeks

          -  History of anorexia nervosa or bulimia

          -  Previous hypersensitivity to bupropion

          -  History of alcohol or other drug dependence in the past one year

          -  History of seizure disorder of any etiology (i.e., brain tumor, traumatic brain
             injury, substance-induced seizures, etc.)

          -  Any finding that in the view of the principal investigator would compromise the
             subject's ability to fulfill the protocol visit schedule and visit requirements or put
             the subject at risk

          -  Sharing home or work environment with current or past participant

          -  No couples or participants who see each other every day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie O'Malley, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Substance Abuse Treatment Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Substance Abuse Treatment Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Toll BA, O'Malley SS, Katulak NA, Wu R, Dubin JA, Latimer A, Meandzija B, George TP, Jatlow P, Cooney JL, Salovey P. Comparing gain- and loss-framed messages for smoking cessation with sustained-release bupropion: a randomized controlled trial. Psychol Addict Behav. 2007 Dec;21(4):534-44.</citation>
    <PMID>18072836</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2005</study_first_submitted>
  <study_first_submitted_qc>March 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2005</study_first_posted>
  <last_update_submitted>August 7, 2013</last_update_submitted>
  <last_update_submitted_qc>August 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Stephanie O'Malley</investigator_full_name>
    <investigator_title>Director, Division of Substance Abuse Research in Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

